Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066220 | 1.00 | ALDH1A1 (0.50) | ALDH1A1NPC1HTTRAB9APPARG | |
| SCHEMBL2153012 | 1.00 | ALDH1A1 (0.50) | ALDH1A1NPC1HTTRAB9APPARG | |
| Hydrochloric Acid SCHEMBL3986125 | 0.98 | ALDH1A1 (0.49) | ALDH1A1NPC1HTTRAB9APPARG | |
| Hydrochloric Acid SCHEMBL32677150 | 0.98 | ALDH1A1 (0.49) | ALDH1A1NPC1HTTRAB9APPARG | |
| Hydrochloric Acid SCHEMBL1066219 | 0.98 | ALDH1A1 (0.49) | ALDH1A1NPC1HTTRAB9APPARG | |
| Hydrochloric Acid SCHEMBL16062182 | 0.98 | ALDH1A1 (0.49) | ALDH1A1NPC1HTTRAB9APPARG | |
| SCHEMBL2152835 | 0.86 | EPHX2 (0.48) | ALDH1A1NPC1PPARGPPARASLC6A2 | |
| SCHEMBL21117782 | 0.86 | EPHX2 (0.48) | ALDH1A1NPC1PPARGPPARASLC6A2 | |
| SCHEMBL2152834 | 0.86 | EPHX2 (0.48) | ALDH1A1NPC1PPARGPPARASLC6A2 | |
| SCHEMBL27168302 | 0.85 | ALDH1A1 (0.40) | ALDH1A1NPC1HTTPTGS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-105142635-B | Heterocyclic compounds useful for the treatment of diseases | 艾匹根生物技术有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-2988743-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-2988743-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | Epigen Biosciences, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014145873-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | ALDH1A1 2204/4885NPC1 1347/4885HTT 2546/4885 |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | LPAR1, LPAR4, LPAR2 | ALDH1A1 1649/4885NPC1 485/4885HTT 3328/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | ALDH1A1 2381/4885NPC1 1331/4885HTT 4610/4885 |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | ALDH1A1 1693/4885NPC1 998/4885HTT 3762/4885 |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | ALDH1A1 1693/4885NPC1 998/4885HTT 3762/4885 |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR4, LPAR3 | ALDH1A1 1621/4885NPC1 1032/4885HTT 3766/4885 |
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | ALDH1A1 4166/4885NPC1 3859/4885HTT 2591/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 1908/4885NPC1 1353/4885HTT 4333/4885 |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR4, LPAR3 | ALDH1A1 1693/4885NPC1 998/4885HTT 3762/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | ALDH1A1 2204/4885NPC1 1347/4885HTT 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.